90 related articles for article (PubMed ID: 19283231)
1. Controversies in type 2 diabetes - An update.
Yeap BB
Aust Fam Physician; 2009; 38(1-2):22-5. PubMed ID: 19283231
[TBL] [Abstract][Full Text] [Related]
2. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Krentz A
Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
[TBL] [Abstract][Full Text] [Related]
3. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular risk and cardiometabolic protection: role of glitazones.
Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
[TBL] [Abstract][Full Text] [Related]
5. The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors.
Edelman SV
Rev Cardiovasc Med; 2003; 4 Suppl 6():S29-37. PubMed ID: 14668701
[TBL] [Abstract][Full Text] [Related]
6. [Challenge in diabetes therapy: effects of glitazones beyond blood glucose control].
Schernthaner G; Forst T; Gulba D; Haberbosch W; Hanefeld M; Linss G; März W; Mehnert H; Rosak C; Schnell O; Seufert J; Tschöpe D; Erdmann E
Dtsch Med Wochenschr; 2009 Apr; 134(18):949-54. PubMed ID: 19384816
[TBL] [Abstract][Full Text] [Related]
7. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
Mazzone T
Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.
Winkelmayer WC; Setoguchi S; Levin R; Solomon DH
Arch Intern Med; 2008 Nov; 168(21):2368-75. PubMed ID: 19029503
[TBL] [Abstract][Full Text] [Related]
9. Pleiotropic effects of thiazolidinediones.
Rizos CV; Liberopoulos EN; Mikhailidis DP; Elisaf MS
Expert Opin Pharmacother; 2008 May; 9(7):1087-108. PubMed ID: 18422468
[TBL] [Abstract][Full Text] [Related]
10. Glitazones and the cardiovascular system.
Devchand PR
Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):188-92. PubMed ID: 18316956
[TBL] [Abstract][Full Text] [Related]
11. PROactive: time for a critical appraisal.
Betteridge DJ; DeFronzo RA; Chilton RJ
Eur Heart J; 2008 Apr; 29(8):969-83. PubMed ID: 18375395
[TBL] [Abstract][Full Text] [Related]
12. Distal upper and lower limb fractures associated with thiazolidinedione use.
Jones SG; Momin SR; Good MW; Shea TK; Patric K
Am J Manag Care; 2009 Aug; 15(8):491-6. PubMed ID: 19670952
[TBL] [Abstract][Full Text] [Related]
13. Balancing risk and benefit with oral hypoglycemic drugs.
Hamnvik OP; McMahon GT
Mt Sinai J Med; 2009 Jun; 76(3):234-43. PubMed ID: 19421967
[TBL] [Abstract][Full Text] [Related]
14. [Heart failure with thiazolidinedione treatment: what do we know today?].
Erdmann E
Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858
[TBL] [Abstract][Full Text] [Related]
15. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
16. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits.
Patel RR
Cardiol Rev; 2009; 17(3):132-5. PubMed ID: 19384087
[TBL] [Abstract][Full Text] [Related]
17. Serum sialic acid changes in non-insulin-dependant diabetes mellitus (NIDDM) patients following bitter melon (Momordica charantia) and rosiglitazone (Avandia) treatment.
Inayat-ur-Rahman ; Malik SA; Bashir M; Khan R; Iqbal M
Phytomedicine; 2009 May; 16(5):401-5. PubMed ID: 19362455
[TBL] [Abstract][Full Text] [Related]
18. Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance.
Lebovitz HE
J Indian Med Assoc; 2008 Nov; 106(11):724-6. PubMed ID: 19368098
[TBL] [Abstract][Full Text] [Related]
19. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14).
Spanheimer R; Betteridge DJ; Tan MH; Ferrannini E; Charbonnel B;
Am J Cardiol; 2009 Jul; 104(2):234-9. PubMed ID: 19576353
[TBL] [Abstract][Full Text] [Related]
20. Long-term pioglitazone therapy improves arterial stiffness in patients with type 2 diabetes mellitus.
Harashima K; Hayashi J; Miwa T; Tsunoda T
Metabolism; 2009 Jun; 58(6):739-45. PubMed ID: 19446110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
